Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Appl Physiol ; 122(11): 2331-2342, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35864343

RESUMO

PURPOSE: Osteopenia is common in postmenopausal women and effective interventions increasing or stabilizing bone mineral density (BMD) to prevent fractures are urgently needed. METHODS: Sixty-five postmenopausal women diagnosed with osteopenia (T-score between -1.0 and -2.5) were randomly assigned to either a vibration training group (VT), a resistance training group (RT), or a control group (CG). BMD T-score values (primary endpoint) were assessed at baseline (T0) and after 12 months (T12), secondary endpoints (muscle strength, postural control, and health-related quality of life) at baseline (T0), after 6 months (T6), after 12 months (T12), and as follow-up after 15 months (T15). RESULTS: After the intervention period, neither the VT nor the RT showed any significant changes in BMD T-score values compared to the CG. Isokinetic strength improved significantly within all training groups, with the exception of the flexors of VT at an angular velocity of 240°/s. Health-related quality of life as well as postural control improved significantly for the RT only. CONCLUSIONS: We conclude that participants of all three groups were able to maintain their BMD. The improvements in quality of life and postural control after resistance training are nevertheless meaningful for postmenopausal osteopenic women and support the importance of regular loadings of the musculoskeletal system. This study was retrospectively registered in January 2022 at the DRKS (S00027816) as clinical trial.


Assuntos
Doenças Ósseas Metabólicas , Osteoporose Pós-Menopausa , Densidade Óssea/fisiologia , Feminino , Humanos , Força Muscular/fisiologia , Osteoporose Pós-Menopausa/prevenção & controle , Pós-Menopausa/fisiologia , Equilíbrio Postural , Qualidade de Vida , Vibração/uso terapêutico
2.
BMC Geriatr ; 16: 52, 2016 Feb 29.
Artigo em Inglês | MEDLINE | ID: mdl-26928275

RESUMO

BACKGROUND: Sarcopenia is a common geriatric syndrome associated with serious adverse health outcomes. The European Working Group on Sarcopenia in Older People (EWGSOP) suggests different methods for case finding for sarcopenia. However, data comparing the different methodological options are scarce for geriatric inpatients. METHODS: On the basis of the recommendations of the EWGSOP sixty geriatric inpatients underwent measurement of gait speed, hand grip strength and muscle mass by both, dual X-ray absorptiometry (DXA) and bioimpedance analysis (BIA). By linear regression analysis and Bland-Altman plots muscle mass measurements of DXA and BIA were compared. Outcomes of the DXA- and BIA-based approaches for classifying participants as having normal or reduced muscle mass and sarcopenia according to the EWGSOP case finding algorithm were compared by raw agreement and kappa statistics. Finally, on the hypothetical assumption that the DXA-based approach can be set as reference, the performance of the BIA-based approach is illustrated. RESULTS: Muscle mass measured by BIA was highly correlated to DXA (r > 0.9), but BIA systematically overestimated muscle mass. The mean difference between DXA and BIA was -1.30 kg (p < 0.001) for appendicular and -2.33 kg (p < 0.001) for total muscle mass. The raw agreement between the DXA- and BIA-based approaches for classifying participants as having normal or reduced muscle mass was at best 80 % depending on the BIA cut-offs used. Functional prescreening according to the sarcopenia case finding algorithm of the EWGSOP reduced the need for muscle mass measurement by 37 %, but only marginally changed the agreement between the DXA- and BIA-based approaches. CONCLUSION: Clinicians should be aware that in geriatric inpatients the BIA-based approaches resulted in highly different subgroups of sarcopenic/non-sarcopenic subjects compared to the DXA-based approach following the EWGSOP case finding algorithm. In this pilot-study the BIA-based approach misclassified nearly 1 out of 6 patients if the DXA-based approach is taken as reference.


Assuntos
Absorciometria de Fóton/métodos , Algoritmos , Marcha/fisiologia , Força da Mão/fisiologia , Pacientes Internados , Músculo Esquelético/diagnóstico por imagem , Sarcopenia/fisiopatologia , Idoso de 80 Anos ou mais , Impedância Elétrica , Feminino , Humanos , Masculino , Músculo Esquelético/fisiopatologia , Projetos Piloto , Prevalência , Sarcopenia/diagnóstico
3.
Eur J Appl Physiol ; 112(5): 1861-71, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21922264

RESUMO

The purpose of this study was to determine whether physical activity, with and without lower body pressure, leads to increased regional fat loss in the lower extremities of overweight females. Eighty-six obese women with a female phenotype were randomly assigned into four groups: control group (C), diet only (D), diet plus exercise (DE) or diet, exercise and lower body pressure intervention (DEP). The three treatment groups followed the same diet, the two exercise groups (DE and DEP) additionally followed an endurance training program of 30 min of cycling at 50%VO(2)max three times per week with or without lower body pressure. Body composition and fat distribution were assessed by DXA. Body size circumference measurements were recorded as well as subjective ratings of cellulite and skin appearance. As expected, all test groups (D, DE, DEP) showed a significant decrease (p < 0.05) in total body mass and fat mass. DXA revealed significant differences between the experimental groups and C. The DEP group also lost significantly more body mass and fat mass when compared with D, while no significant difference was observed between the other groups. A similar pattern was seen for circumference measurement data. A significant perceived improvement was made by the DEP group when compared with C, D and DE groups for skin condition and also between the DEP versus C and D groups for cellulite. The combination of diet and exercise is successful for weight reduction. The additional application of lower body pressure especially affects skin appearance.


Assuntos
Distribuição da Gordura Corporal , Dieta Redutora , Terapia por Exercício , Exercício Físico/fisiologia , Sobrepeso/terapia , Pele , Absorciometria de Fóton , Adulto , Índice de Massa Corporal , Terapia Combinada , Dieta Redutora/métodos , Teste de Esforço , Terapia por Exercício/métodos , Feminino , Humanos , Pessoa de Meia-Idade , Sobrepeso/dietoterapia , Sobrepeso/fisiopatologia , Redução de Peso
4.
Lancet Oncol ; 9(9): 840-9, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18718815

RESUMO

BACKGROUND: The Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) bone substudy assesses zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuvant treatment with or without zoledronic acid. The aim of this substudy is to gain insight into bone health in this setting. METHODS: ABCSG-12 is a randomised, open-label, phase III, 4-arm trial comparing tamoxifen (20 mg/day orally) and goserelin (3.6 mg subcutaneously every 28 days) versus anastrozole (1 mg/day orally) and goserelin (3.6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer. This prospective bone subprotocol measured BMD at 0, 6, 12, 36, and 60 months. The primary endpoint of the bone substudy (secondary endpoint in the main trial) was change in BMD at 12 months, assessed by dual-energy X-ray absorptiometry in assessable patients. Analyses were intention to treat. Statistical significance was assessed by t tests. The ABCSG-12 trial is registered on the ClinicalTrials.gov website, number NCT00295646. FINDINGS: 404 patients were prospectively included in the bone substudy and randomly assigned to endocrine therapy alone (goserelin and anastrozole or goserelin and tamoxifen; n=199) or endocrine therapy concurrent with zoledronic acid (goserelin, anastrozole, and zoledronic acid or goserelin, tamoxifen, and zoledronic acid; n=205). After 3 years of treatment, endocrine therapy alone caused significant loss of BMD at the lumbar spine (-11.3%, mean difference -0.119 g/cm(2) [95% CI -0.146 to -0.091], p<0.0001) and trochanter (-7.3%, mean difference -0.053 g/cm(2) [-0.076 to -0.030], p<0.0001). In patients who did not receive zoledronic acid, anastrozole caused greater BMD loss than tamoxifen at 36 months at the lumbar spine (-13.6%, mean difference -0.141 g/cm(2) [-0.179 to -0.102] vs -9.0%, mean difference -0.095 g/cm(2) [-0.134 to -0.057], p<0.0001 for both). 2 years after the completion of treatment (median follow-up 60 months [range 15.5-96.6]), patients not receiving zoledronic acid still had decreased BMD at both sites compared with baseline (lumbar spine -6.3%, mean difference -0.067 g/cm(2) [-0.106 to -0.027], p=0.001; trochanter -4.1%, mean difference -0.03 g/cm(2) [-0.062 to 0.001], p=0.058). Patients who received zoledronic acid had stable BMD at 36 months (lumbar spine +0.4%, mean difference 0.004 g/cm(2) [-0.024 to 0.032]; trochanter +0.8%, mean difference 0.006 g/cm(2) [-0.018 to 0.028]) and increased BMD at 60 months at both sites (lumbar spine +4.0%, mean difference 0.039 g/cm(2) [0.005-0.075], p=0.02; trochanter +3.9%, mean difference 0.028 g/cm(2) [0.003-0.058], p=0.07) compared with baseline. INTERPRETATION: Goserelin plus tamoxifen or anastrozole for 3 years without concomitant zoledronic acid caused significant bone loss. Although there was partial recovery 2 years after completing treatment, patients receiving endocrine therapy alone did not recover their baseline BMD levels. Concomitant zoledronic acid prevented bone loss during therapy and improved BMD at 5 years.


Assuntos
Antineoplásicos Hormonais/administração & dosagem , Conservadores da Densidade Óssea/administração & dosagem , Doenças Ósseas Metabólicas/prevenção & controle , Neoplasias da Mama/tratamento farmacológico , Difosfonatos/administração & dosagem , Imidazóis/administração & dosagem , Osteoporose/prevenção & controle , Adulto , Anastrozol , Antineoplásicos Hormonais/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Densidade Óssea/efeitos dos fármacos , Doenças Ósseas Metabólicas/induzido quimicamente , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Difosfonatos/farmacologia , Feminino , Gosserrelina/administração & dosagem , Humanos , Imidazóis/farmacologia , Modelos Lineares , Nitrilas/administração & dosagem , Osteoporose/induzido quimicamente , Pré-Menopausa , Estudos Prospectivos , Tamoxifeno/administração & dosagem , Triazóis/administração & dosagem , Ácido Zoledrônico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa